Document Detail


The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I.
MedLine Citation:
PMID:  19384451     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Dosimetry studies have shown that activities of 131I as small as 10-20 MBq may cause a stunning effect. A result of this stunning effect may be a lower success rate of the ablative 131I therapy for differentiated thyroid carcinoma (DTC). The aim of this study was to determine whether pre-therapeutic uptake measurement with 40 MBq 131I causes a lower success rate of ablation. DESIGN: retrospective chart review study. PATIENTS, METHODS: In two hospitals the ablation protocols differed in one respect only: in the one hospital no diagnostic 131I was applied before ablation (group 1, n = 48), whereas in the other hospital a 24-h uptake-measurement with 40 MBq 131I was performed (group 2, n = 51). Included were all DTC patients without distant metastases who had undergone 131I ablation between July 2002 and December 2005, and who had returned for 131I follow-up. Successful ablation was defined as absence of pathological 131I uptake on diagnostic whole-body scintigraphy and undetectable thyroglobulin-levels under TSH stimulation. RESULTS: Overall, ablation was successful in 31/48 patients (65%) in group 1 and in 17/51 patients (33%) in group 2 (p=0.002). Multivariate analysis showed that pre-therapeutic uptake measurement using 40 MBq 131I was an independent determinant for success of ablation (p = 0.002). CONCLUSIONS: After applying a diagnostic activity of 40 MBq 131I before ablation, the success rate of ablation is severely reduced. Consequently, the routine application of 131I for diagnostic scintigraphy or uptake measurement prior to 131I ablation is best avoided.
Authors:
F A Verburg; R B T Verkooijen; M P M Stokkel; J W van Isselt
Publication Detail:
Type:  Journal Article     Date:  2009-04-22
Journal Detail:
Title:  Nuklearmedizin. Nuclear medicine     Volume:  48     ISSN:  0029-5566     ISO Abbreviation:  Nuklearmedizin     Publication Date:  2009  
Date Detail:
Created Date:  2009-08-04     Completed Date:  2010-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7609387     Medline TA:  Nuklearmedizin     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  138-42; quiz N19-20     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine, University Medical Center Utrecht. Verburg_e@klinik.uni-wuerzburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Follow-Up Studies
Humans
Iodine Radioisotopes / diagnostic use,  therapeutic use*
Lymphatic Metastasis
Male
Neoplasm Invasiveness
Radiopharmaceuticals / diagnostic use,  therapeutic use
Radiotherapy Dosage
Thyroid Neoplasms / pathology,  radiotherapy*,  surgery
Thyroidectomy
Treatment Outcome
Chemical
Reg. No./Substance:
0/Iodine Radioisotopes; 0/Radiopharmaceuticals

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Kinetic analysis of experimental rabbit tumour and inflammation model with 18F-FDG PET/CT.
Next Document:  Myocardial perfusion scintigraphy 2007 in Germany--results of the query and current status